IRBESARTAN/HYDROCHLOROTHIAZIDE MYLAN PHARMA 150 mg/12.5 mg, film-coated tablet 30 tablets
Active ingredients: HYDROCHLOROTHIAZIDE, Irbesartan
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IRBESARTAN/HYDROCHLOROTHIAZIDE MYLAN PHARMA 150 mg/12,5 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s)
- Marketing authorisation holder
- MYLAN SAS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 22 Dec 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67399371CIP72178216CIP133400921782165Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| HYDROCHLOROTHIAZIDEcomprimé | 12,5 mg · un comprimé | SA |
| IRBÉSARTANcomprimé | 150 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.